The results are dose dependent and apparently can be fixed that way.
What you're saying is misleading.
Novartis was apparently looking for an excuse because they were making a commercial decision based on their speculation of what they think (and hope) is going to be a better deal. There are other murkier aspects covered in posts of others,
Teva did the same thing ..... And flamed out!
the dogs bark but the MSB caravan moves on
Novartis walked due to "sub par data"., page-129
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
89.5¢ |
Change
-0.020(2.19%) |
Mkt cap ! $1.021B | |||
| Open | High | Low | Value | Volume |
| 90.5¢ | 90.5¢ | 89.5¢ | $1.404M | 1.564M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 163115 | 89.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 90.0¢ | 119119 | 33 |
View Market Depth
| Last trade - 11.00am 08/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |